ReviewCurrent cancer drug targets2026
CircRNAs Regulate Senescence-Associated miRNAs in Gastric Cancer.
Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gastric cancer is closely associated with the aging process, with its incidence and mortality rates significantly increasing with age, peaking around 85 years. Despite advancements in treatment modalities, current diagnostic and therapeutic approaches remain insufficient, resulting in persistently low five-year survival rates among patients. The expanding global population and the intensifying aging process are anticipated to exacerbate the global burden of gastric cancer further, underscoring the urgency of exploring novel therapeutic strategies. A complex relationship exists between gastric cancer and cellular senescence, although the precise mechanisms remain incompletely understood. Cellular senescence is prevalent in gastric cancer treatment, typically serving as a natural anti-tumor barrier by inhibiting the uncontrolled proliferation and malignant transformation of cancer cells. However, prolonged cellular senescence may trigger the secretion of pro-inflammatory factors, thereby promoting tumorigenesis and progression. A systematic analysis of existing research data has revealed significant intersections between therapeutic targets for gastric cancer and senescence-associated signaling pathways, suggesting that modulating these critical nodes may constitute a pivotal mechanism for exploring novel therapeutic strategies bridging gastric cancer treatment and senescence. Circular RNAs (circRNAs) have garnered considerable attention with the advancement of bioinformatics and high-throughput sequencing technologies. As key regulatory factors, circRNAs can modulate microRNAs (miRNAs) through a "sponge adsorption" mechanism, thereby influencing the post-transcriptional modification of critical genes. Given their high structural stability and widespread distribution in vivo, circRNAs have emerged as ideal candidate molecules for biomarkers and therapeutic targets in gastric cancer. This review focuses on the mechanisms by which circRNAs, through sponging miRNAs, regulate key nodes in therapeutic targets and senescence signaling pathways in gastric cancer.
Indexed as
Identifiers
40605161What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.